Abstracts tagged "neutrophils and toll-like receptors"

Abstract Number: 1006 • 2018 ACR/ARHP Annual Meeting
Physical Activity at Lower Intensities Reduces Localized IL-1b in a Murine Model of Gout By Systemically Down-Regulating TLR2 Expression on Circulating Neutrophils and Suppressing CXCL1 Expression
Kyle Jablonski¹, Nicholas A. Young², Bianca Sandoval³, Ifeoma Okafor⁴, Emily Schwarz³, Caitlin Henry³, Peter Harb³, Anuradha Kalyanasundaram⁵, Wael Jarjour⁶ and Naomi Schlesinger⁷, ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Rheumatology and Immunology, Columbus, OH, ⁴Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Physiology and Cell Biology, The Ohio State University, Columbus, OH, ⁶Department of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁷Department of Medicine/Rheumatology Division, Rutgers- Robert Wood Johnson Medical School, New Brunswick, New Brunswick, NY
Background/Purpose: Exercise was originally believed to exacerbate inflammation in rheumatic disease, however, recent studies have shown that regular physical activity is anti-inflammatory. In gout, there…
Abstract Number: 1731 • 2013 ACR/ARHP Annual Meeting
Treatment Of Innate Immune Arthritis With a Toll-Like Receptor 7 Agonist Requires Type I Interferon
Maripat Corr¹, Tomoko Hayashi², Dennis A. Carson³, Howard Cottam⁴ and Joshua Yang³, ¹Medicine, Univ of California-San Diego, La Jolla, CA, ²Medicine, UCSD School of Medicine, La Jolla, CA, ³UCSD School of Medicine, La Jolla, CA, ⁴ucsd School of Medicine, La Jolla, CA
Background/Purpose: We previously demonstrated that repeated administration of the low molecular weight Toll-like receptor (TLR) 7 agonist (1V136) substantially reduces arthritic inflammation in mice. Here…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].